HIV vax researchers ponder best R&D strategies

Emboldened by a glimpse of the potential of a new HIV vaccine, more than 1,000 researchers from around the world are gathering in Atlanta this week to share their thoughts on the best strategies for finally finding a shot which can guard against the lethal virus. "Over the past year, scientists have identified neutralizing antibodies against HIV, which are a fundamental building block for developing a vaccine," Mitchell Warren, executive director of the Aids Vaccine Advocacy Coalition, tells the Guardian. Story

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.